Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: limit (519), stricture (9), limitation (67), restriction (110), constraint (36), bound (115)

BEACON protocol v8.0 07Mar2023 signed

Description: A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory
Url: /Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

DH IVIg approved indications full guidance July 2011

Description: DH INFORMATION READER BOX Policy HR / Workforce Management Planning / Clinical Performance Document Purpose Gateway Reference Title Author Publication Date Target Audienc
Url: /Media/SUHTExtranet/TrustMedicinesFormulary/Forms/DH-IVIg-approved-indications-Full-Guidance-July-2011.pdf

Annual-report-and-quality-account-2019-20

Description: ANNUAL REPORT AND ACCOUNTS 2019/20 Incorporating the quality account 2019/20 Page 2 University Hospital Southampton NHS Foundation Trust Annual
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-and-quality-account-2019-202.pdf

InP-Etoposide-Ifosfamide (3 day) v2

Description: Chemotherapy Protocol SARCOMA ETOPOSIDE-IFOSFAMIDE (3 day) Inpatient Regimen Regimen • Sarcoma-InP-Etoposide-Ifosfamide (3 day) Indication • Second line treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InP-Etoposide-Ifosfamide-3-day-v2.pdf

InPEtoposideIfosfamide(5dy)Ver1

Description: Chemotherapy Protocol SARCOMA ETOPOSIDE-IFOSFAMIDE (5 day) Inpatient Regimen Regimen Sarcoma-InP-Etoposide-Ifosfamide (5 day) Indication Second line treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InPEtoposideIfosfamide5dyVer1.pdf

InP-Cisplatin-Ifosfamide-Paclitaxel (TIP) Ver1.2

Description: Chemotherapy Protocol GERM CELL CISPLATIN-IFOSFAMIDE-PACLITAXEL (TIP) Inpatient Regimen Regimen Germ Cell – InP-Cisplatin-Ifosfamide-Paclitaxel (TIP) Indication Relapsed Metastatic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Germcell/InP-Cisplatin-Ifosfamide-Paclitaxel-TIP-Ver1.2.pdf

Ruxolitinib

Description: Chemotherapy Protocol Myelofibrosis Ruxolitinib Regimen • Myelofibrosis – Ruxolitinib Indication • Ruxolitinib is recommended as an option for treating disease-related splenomegaly or symptoms
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myelofibrosis/Ruxolitinib.pdf

Azacitidine5

Description: Chemotherapy Protocol Myelodysplastic Syndrome (MDS) Acute Myeloid Leukaemia (AML) Chronic Myelomonocytic Leukaemia (CMML) Azacitidine SC (5 days) This is an unlicensed
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Azacitidine5.pdf

Azacitidine5+2Ver1

Description: Chemotherapy Protocol Myelodysplastic Syndrome (MDS) Acute Myeloid Leukaemia (AML) Chronic Myelomonocytic Leukaemia (CMML) Azacitidine SC (5+2 days) This is not
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Azacitidine5-2Ver1.pdf

Cyclophosphamide-Prednisolone-Rituximab- R-CP (21)

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-PREDNISOLONE-RITUXIMAB (R-CP) Regimen • Lymphoma – R-CP (21)-Cyclophosphamide-Prednisolone-Rituximab Indication • Lymphoplasmacytic lymphoma/Waldenstrom’s
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Cyclophosphamide-Prednisolone-Rituximab-R-CP-21.pdf

1 to 10 of 132

Previous 1 2 3 4 5 … Next